Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study

Who May Qualify: - Consent and sign the willing to sign a consent form form - Non-low-risk PAH treatment-naive patients Who Should NOT Join This Trial: - Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension - Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary - Pregnant or lactating women - Suffering from mental illness or cognitive impairment - PAH patients with concurrent malignant tumors - Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia - Currently participating in other interventional clinical studies - Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study. Always talk to your doctor about whether this trial is right for you.